Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: Implications for treatment of OHSS with dopamine receptor 2 agonists

Fertility and Sterility

Volumn 102, Issue 5, 2014, Pages 1468-1476.e1

  Ferrero, Hortensia ^a   García Pascual, Carmen M ^a   Gaytán, María ^b   Morales, Concepción ^c   Simón, Carlos ^a   Gaytán, Francisco ^c   Pellicer, Antonio ^a   Gómez, Raúl ^a  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b IVI Madrid   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Animal model; Dopamine receptor 2 agonists; OHSS; VEGF

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GONADOTROPIN; MESSENGER RNA; PROGESTERONE; SERIC GONADOTROPIN; VASCULOTROPIN; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS LUTEUM; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; EXPERIMENTAL STUDY; EXTRAVASATION; FEMALE; GENE EXPRESSION; IMAGE ANALYSIS; IN VIVO STUDY; LUTEAL PHASE; NONHUMAN; OUTCOME ASSESSMENT; OVARY FUNCTION; OVARY HYPERSTIMULATION; PILOT STUDY; PRIORITY JOURNAL; PROGESTERONE RELEASE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; THECA CELL; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; SECRETION (PROCESS); TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922130597     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2014.07.1240     Document Type: Article

References (34)

1. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003;349:729-32.
2. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-77.
3. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978-85.
4. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-6.
5. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967-71.
6. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-8.
7. Gómez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339-48.
8. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
9. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-97.
10. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321-33.
11. Agrawal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, et al. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 1998;70:651-8.
12. Humaidan P, Quartarolo J, Papanikolau EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;94:389-400.
13. Cristina C, Díaz-Torga G, Baldi A, Góngora A, Rubinstein M, Low MJ, et al. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 2005;146:2952-62.
14. Gómez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low dose dopamine agonist administration blocks VEGF mediated vascular permeability without altering VEGFR-2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-11.
15. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228-38.
16. Álvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-4.
17. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997;20:547-55.
18. Mornex R, Orgiazzi J, Hugues B, Gagnaire JC, Claustrat B. Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab 1978;47:290-5.
19. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413-20.
20. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74.
21. Sinha S, Vohra PK, Bhattacharya R, Dutta S, Sinha S, Mukhopadhyay D. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J Cell Sci 2009;122:3385-92.
22. Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459-66.
23. Ferrero H, García-Pascual CM, Gómez R, Delgado-Rosas F, Cauli O, Simón C, et al. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists. Fertil Steril 2014;101:1411-8.
24. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003;162:1881-93.
25. Ujioka T, Matsuura K, Kawano T, Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod 1997;12:1629-34.
26. Kitajima Y, Endo T, Manase K, Nishikawa A, Shibuya M, Kudo R. Gonadotropin releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril 2004;81(Suppl 1):842-9.
27. Wu Y, Wu M, He G, Zhang X, Li W, Gao Y, et al. Glyceraldehyde-3-phosphate dehydrogenase: a universal internal control for Western blots in prokaryotic and eukaryotic cells. Anal Biochem 2012;423:15-22.
28. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7.
29. Busso C, Fernández-Sánchez M, García-Velasco JA, Landeras J, Ballesteros A, Muñoz E, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25:995-1004.
30. Sherwal V, Malik S, Bhatia V. Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. J Hum Reprod Sci 2010;3:85-90.
31. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751-5.
32. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 1995;146:157-65.
33. Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004;23:434-45.
34. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, TrounsonA.Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180-3.